請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77450
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊家榮(Chia-Ron Yang) | |
dc.contributor.author | Jou-Man Huang | en |
dc.contributor.author | 黃柔嫚 | zh_TW |
dc.date.accessioned | 2021-07-10T22:02:33Z | - |
dc.date.available | 2021-07-10T22:02:33Z | - |
dc.date.copyright | 2019-03-11 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-11-02 | |
dc.identifier.citation | 1. Alzheimer’s, A. Alzheimer’s disease facts and figures. Alzheimers Dement. 2018; 14: 367–429.
2. Kumar K, Kumar A, Keegan RM, Deshmukh R. Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease. Biomed Pharmacother. 2018; 98: 297–307. 3. Zhang L, Fang Y, Xu XF, Jin DY. Moscatilin induces apoptosis of pancreatic cancer cells via reactive oxygen species and the JNK/SAPK pathway. Mol Med Rep. 2017; 15: 1195–1203. 4. Busaranon K, Plaimee P, Sritularak B, Chanvorachote P. Moscatilin inhibits epithelial-to-mesenchymal transition and sensitizes anoikis in human lung cancer H460 cells. J Nat Med. 2016; 70: 18–27. 5. Chen CA, Chen CC, Shen CC, Chang HH, Chen YJ. Moscatilin induces apoptosis and mitotic catastrophe in human esophageal cancer cells. J Med Food. 2013; 16: 869–77. 6. Kowitdamrong A, Chanvorachote P, Sritularak B, Pongrakhananon V. Moscatilin inhibits lung cancer cell motility and invasion via suppression of endogenous reactive oxygen species. Biomed Res Int. 2013; 2013: 765894. 7. Pai HC, Chang LH, Peng CY, Chang YL, Chen CC, Shen CC, Teng CM, Pan SL. Moscatilin inhibits migration and metastasis of human breast cancer MDA-MB-231 cells through inhibition of Akt and Twist signaling pathway. J Mol Med (Berl). 2013; 91: 347–56. 8. Tsai AC, Pan SL, Liao CH, Guh JH, Wang SW, Sun HL, Liu YN, Chen CC, Shen CC, Chang YL, Teng CM. Moscatilin, a bibenzyl derivative from the India orchid Dendrobrium loddigesii, suppresses tumor angiogenesis and growth in vitro and in vivo. Cancer Lett. 2010; 292: 163–70. 9. Liu YN, Pan SL, Peng CY, Huang DY, Guh JH, Chen CC, Shen CC, Teng CM. Moscatilin repressed lipopolysaccharide-induced HIF-1alpha accumulation and NF-kappaB activation in murine RAW264.7 cells. Shock. 2010; 33: 70–5. 10. Chen TH, Pan SL, Guh JH, Liao CH, Huang DY, Chen CC, Teng CM. Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-Jun NH2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage. Clin Cancer Res. 2008; 14: 4250–8. 11. Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018; 25: 59–70. 12. Sawda C, Moussa C, Turner RS. Resveratrol for Alzheimer's disease. Ann. N. Y. Acad. Sci. 2017; 1403: 142–149 13. Chopra K, Misra S, Kuhad A. Neurobiological aspects of Alzheimer's disease. Expert Opin Ther Targets. 2011; 15: 535–55. 14. Danysz W, Parsons CG. Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol. 2012; 167: 324–52. 15. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol. 2010; 223: 252–66. 16. Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis. 2010; 19: 311–23. 17. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018; 14: 450–464. 18. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta. 2005; 1739: 198–210. 19. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016; 17: 5–21. 20. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev. 2013; 12: 289–309. 21. Augustinack JC1, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002; 103: 26–35. 22. Martin L, Page G, Terro F. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β. Neurochem Int. 2011; 59: 235–50. 23. Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010; 223: 322–325. 24. Llorens-Martín M, Jurado J, Hernández F, Avila J. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014; 7: 46. 25. Noel A, Barrier L, Ingrand S. The Tyr216 phosphorylated form of GSK3β contributes to tau phosphorylation at PHF-1 epitope in response to Aβ in the nucleus of SH-SY5Y cells. Life Sci. 2016; 158: 14–21. 26. Muyllaert D, Terwel D, Borghgraef P, Devijver H, Dewachter I, Van Leuven F. Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology. Rev Neurol (Paris). 2006; 162: 903–907. 27. Cho JH, Johnson GV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem. 2004; 88: 349–58. 28. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem. 2003; 278: 187–93. 29. Engmann O, Giese KP. Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's Disease. Front Mol Neurosci. 2009; 2: 2. 30. Lee JK, Kim NJ. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease. Molecules. 2017; 22. 31. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. 2010; 58: 561–8. 32. Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals. 2002; 11: 270–81. 33. Cheung ZH, Ip NY. Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 2012; 22: 169–75. 34. Noble W, Olm V, Takata K, Casey E, Mary O, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003; 38: 555–65. 35. Castro-Alvarez JF, Uribe-Arias SA, Mejía-Raigosa D, Cardona-Gómez GP. Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach. Front Aging Neurosci. 2014; 6: 232. 36. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem. 2008; 15: 2321–8. 37. Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules. 2016; 6: 6. 38. Kumar A, Tsao JW. Alzheimer Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018. 39. Li LS, Lu YL, Nie J, Xu YY, Zhang W, Yang WJ, et al Dendrobium nobile Lindl alkaloid, a novel autophagy inducer, protects against axonal degeneration induced by Aβ25-35 in hippocampus neurons in vitro. CNS Neurosci Ther. 2017; 23: 329–340. 40. Yang S, Gong Q, Wu Q, Li F, Lu Y, Shi J. Alkaloids enriched extract from Dendrobium nobile Lindl. attenuates tau protein hyperphosphorylation and apoptosis induced by lipopolysaccharide in rat brain. Phytomedicine. 2014; 21: 712–6. 41. Kamat PK, Rai S, Nath C. Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer's disease pathology. Neurotoxicology. 2013; 37: 163–72. 42. Kamat PK, Rai S, Swarnkar S, Shukla R, Nath C. Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application. Mol Neurobiol. 2014; 50: 852–65. 43. Chen Y, Wang C, Hu M, Pan J, Chen J, Duan P, Zhai T, Ding J, Xu C. Effects of ginkgolide A on okadaic acid-induced tau hyperphosphorylation and the PI3K-Akt signaling pathway in N2a cells. Planta Med. 2012; 78: 1337–41. 44. Zhou XW, Gustafsson JA, Tanila H, Bjorkdahl C, Liu R, Winblad B, Pei JJ. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis. 2008; 31: 386–394. 45. Zhang Z, Simpkins JW. Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. Brain Res. 2010; 1345: 176–81. 46. Yoon SY, Choi JE, Huh JW, Hwang O, Nam Hong H, Kim D. Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: relevance to Alzheimer's disease. Neuroreport. 2005; 16: 223–7. 47. Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res. 2009; 1252: 66–75. 48. Lim YW, Yoon SY, Choi JE, Kim SM, Lee HS, Choe H, Lee SC, Kim DH. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem Biophys Res Commun. 2010; 395: 207–12. 49. Wu X, Kosaraju J, Tam KY. SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3β activity in SH-SY5Y cells. Eur J Pharm Sci. 2017; 110: 101–108. 50. Hu JP, Xie JW, Wang CY, Wang T, Wang X, Wang SL, Teng WP, Wang ZY. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. Brain Res Bull. 2011; 85: 194–200. 51. Del Barrio L, Martín-de-Saavedra MD, Romero A, Parada E, Egea J, et al. Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and β2* nicotinic stimulation. Toxicol Sci. 2011; 123: 193–205. 52. Yoon S1, Choi J, Yoon J, Huh JW, Kim D. Okadaic acid induces JNK activation, bim overexpression and mitochondrial dysfunction in cultured rat cortical neurons. Neurosci Lett. 2006; 394: 190–5. 53. Pei JJ1, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol. 2003; 163: 845–58. 54. Jiang W, Luo T, Li S, Zhou Y, Shen XY, He F, Xu J, Wang HQ. Quercetin Protects against Okadaic Acid-Induced Injury via MAPK and PI3K/Akt/GSK3β Signaling Pathways in HT22 Hippocampal Neurons. PLoS One. 2016; 11: e0152371. 55. Ahn JH, So SP, Kim NY, Kim HJ, Yoon SY, Kim DH. c-Jun N-terminal Kinase (JNK) induces phosphorylation of amyloid precursor protein (APP) at Thr668, in okadaic acid-induced neurodegeneration. BMB Rep. 2016; 49: 376–81. 56. Costa AP, Tramontina AC, Biasibetti R, Batassini C, Lopes MW, et al. Neuroglial alterations in rats submitted to the okadaic acid-induced model of dementia. Behav Brain Res. 2012; 226: 420–7. 57. Vogel J, Anand VS, Ludwig B, Nawoschik S, Dunlop J, Braithwaite SP. The JNK pathway amplifies and drives subcellular changes in tau phosphorylation. Neuropharmacology. 2009; 57: 539–50. 58. Zhao WQ, Feng C, Alkon DL. Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. Neurobiol Dis. 2003; 14: 458–69. 59. Arias C, Sharma N, Davies P, Shafit-Zagardo B. Okadaic acid induces early changes in microtubule-associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. J Neurochem. 1993; 61: 673–82. 60. Arias C, Becerra-García F, Arrieta I, Tapia R. The protein phosphatase inhibitor okadaic acid induces heat shock protein expression and neurodegeneration in rat hippocampus in vivo. Exp Neurol. 1998; 153: 242–54. 61. Kwon SH, Lee HK, Kim JA, Hong SI, Kim HC, et al. Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. Eur J Pharmacol. 2010; 649: 210–7 62. Park JH, Choi HY, Cho JH, Kim IH, Lee TK, Lee JC, et al. Effects of Chronic Scopolamine Treatment on Cognitive Impairments and Myelin Basic Protein Expression in the Mouse Hippocampus. J Mol Neurosci. 2016; 59: 579–89. 63. Goverdhan P, Sravanthi A, Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis. 2012; 2012: 974013. 64. Jeong EJ, Lee KY, Kim SH, Sung SH, Kim YC. Cognitive-enhancing and antioxidant activities of iridoid glycosides from Scrophularia buergeriana in scopolamine-treated mice. Eur J Pharmacol. 2008; 588: 78–84. 65. Pariyar R, Yoon CS, Svay T, Kim DS, Cho HK, et al. Vitis labruscana leaf extract ameliorates scopolamine-induced impairments with activation of Akt, ERK and CREB in mice. Phytomedicine. 2017; 36: 8–17. 66. Bihaqi SW, Singh AP, Tiwari M. Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and Amyloid precursor protein (AβPP) expression in rat brain. Indian J Pharmacol. 2012; 44: 593–598. 67. Safar MM, Arab HH, Rizk SM, El-Maraghy SA. Bone Marrow-Derived Endothelial Progenitor Cells Protect Against Scopolamine-Induced Alzheimer-Like Pathological Aberrations. Mol Neurobiol. 2016; 53:1403–1418. 68. Li L, Liu J, Yan X, Qin K, Shi M, Lin T, Zhu Y, Kang T, Zhao G. Protective effects of ginsenoside Rd against okadaic acid-induced neurotoxicity in vivo and in vitro. J Ethnopharmacol. 2011; 138: 135–41. 69. Wang Y, Xia Y, Kuang D, Duan Y, Wang G. PP2A regulates SCF-induced cardiac stem cell migration through interaction with p38 MAPK. Life Sci. 2017; 191: 59–67. 70. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007; 2: 322–8. 71. Yamada M, Chiba T, Sasabe J, Terashita K, Aiso S, Matsuoka M. Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmacology. 2008; 33: 2020–32. 72. Weon JB, Jung YS, Ma CJ. Cognitive-Enhancing Effect of Dianthus superbus var. Longicalycinus on Scopolamine-Induced Memory Impairment in Mice. Biomol Ther (Seoul). 2016; 24: 298–304. 73. Brandt R, Léger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol. 1995; 131: 1327–40. 74. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci USA. 2003; 100: 721–6. 75. Lin J, Huang L, Yu J, Xiang S, Wang J, Zhang J, et al. Fucoxanthin, a Marine Carotenoid, Reverses Scopolamine-Induced Cognitive Impairments in Mice and Inhibits Acetylcholinesterase in Vitro. Mar Drugs. 2016; 14. 76. Avila J, León-Espinosa G, García E, García-Escudero V, Hernández F, Defelipe J. Tau Phosphorylation by GSK3 in Different Conditions. Int J Alzheimers Dis. 2012; 2012: 578373. 77. Lei P1, Ayton S, Bush AI, Adlard PA. GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis. 2011; 2011: 189246. 78. Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem. 2005; 280: 3963–73. 79. Deters N, Ittner LM, Götz J. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci. 2008; 28: 137–47. 80. Lim J, Balastik M, Lee TH, Nakamura K, Liou YC, Sun A, Finn G, Pastorino L, Lee VM, Lu KP. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest. 2008; 118: 1877–89. 81. Kremer A, Maurin H, Demedts D, Devijver H, Borghgraef P, Van Leuven F. Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice. J Neurosci. 2011; 31: 18036–47. 82. Landrieu I, Smet-Nocca C, Amniai L, Louis JV, Wieruszeski JM, Goris J, Janssens V, Lippens G. Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PLoS One. 2011; 6: e21521. 83. Gupta R, Gupta LK, Mediratta PK, Bhattacharya SK. Effect of resveratrol on scopolamine-induced cognitive impairment in mice. Pharmacol Rep. 2012; 64: 438–44. 84. Sharma AC1, Kulkarni SK. Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiatry. 1992; 16: 117–25. 85. Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology (Berl). 1990; 101: 27–33. 86. Tenreiro S, Eckermann K, Outeiro TF. Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci. 2014; 7: 42. 87. Jouanne M, Rault S, Voisin-Chiret AS. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents. Eur J Med Chem. 2017; 139: 153–167. 88. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017; 38: 1205–1235. 89. Falsafi SK, Deli A, Höger H, Pollak A, Lubec G. Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems. PLoS One. 2012; 7: e32082. 90. Baral S, Cho DH, Pariyar R, Yoon CS, Chang BY, Kim DS, Cho HK, Kim SY, Oh H, Kim YC, Kim J, Seo J. The Ameliorating Effect of Myrrh on Scopolamine-Induced Memory Impairments in Mice. Evid Based Complement Alternat Med. 2015; 2015: 925432. 91. Park SJ, Ahn YJ, Oh SR, Lee Y, Kwon G, Woo H, Lee HE, Jang DS, Jung JW, Ryu JH. Amyrin attenuates scopolamine-induced cognitive impairment in mice. Biol Pharm Bull. 2014; 37: 1207-13. 92. Xu H., Wang Z. Dendrobium nobile Lindl. 石斛 (Shihu, Dendrobium). Dietary Chinese Herbs. 2015 Springer, Vienna 93. Zhou J, Yang WS, Suo DQ, Li Y, Peng L, Xu LX, Zeng KY, Ren T, Wang Y, Zhou Y, Zhao Y, Yang LC, Jin X. Moringa oleifera Seed Extract Alleviates Scopolamine-Induced Learning and Memory Impairment in Mice. Front Pharmacol. 2018; 9: 389. 94. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y). 2018; 4: 195-214. 95. Duncan T, Valenzuela M. Alzheimer's disease, dementia, and stem cell therapy. Stem Cell Res Ther. 2017; 8: 111. 96. Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer's disease. J Biomed Sci. 2017; 24: 47. 97. Bachurin SO, Bovina EV, Ustyugov AA. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. Med Res Rev. 2017; 37: 1186-1225. 98. Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer's Disease Therapy and Prevention Strategies. Annu Rev Med. 2017; 68: 413-430. 99. Rajasekar N, Dwivedi S, Tota SK, Kamat PK, Hanif K, Nath C, Shukla R. Neuroprotective effect of curcumin on okadaic acid induced memory impairment in mice. Eur J Pharmacol. 2013; 715: 381-94. 100. Kamat PK, Tota S, Saxena G, Shukla R, Nath C. Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res. 2010; 1309: 66-74. 101. Túnez I, Muñoz Mdel C, Feijóo M, Muñoz-Castañeda JR, Bujalance I, Valdelvira ME, Montilla López P. Protective melatonin effect on oxidative stress induced by okadaic acid into rat brain. J Pineal Res. 2003; 34: 265-8. 102. Yuan ZZ, Suo YR, Hao XY, Wang SL, Li G, Wang HL. Triterpenic Acids from Potentilla parvifolia and Their Protective Effects against Okadaic Acid Induced Neurotoxicity in Differentiated SH-SY5Y Cells. Biol Pharm Bull. 2018; 41: 885-890. 103. Ravindran J, Gupta N, Agrawal M, Bala Bhaskar AS, Lakshmana Rao PV. Modulation of ROS/MAPK signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism. Apoptosis. 2011; 16: 145-61. 104. Cakir M, Duzova H, Tekin S, Taslıdere E, Kaya GB, Cigremis Y, Ozgocer T, Yologlu S. ACA, an inhibitor phospholipases A2 and transient receptor potential melastatin-2 channels, attenuates okadaic acid induced neurodegeneration in rats. Life Sci. 2017; 176: 10-20. 105. Xiong YF, Chen Q, Chen J, Zhou J, Wang HX. Melatonin reduces the impairment of axonal transport and axonopathy induced by calyculin A. J Pineal Res. 2011; 50: 319-27. 106. Yang X, Yang Y, Fu Z, Li Y, Feng J, Luo J, Zhang Q, Wang Q, Tian Q. Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol. 2011; 25: 1118-25. 107. Liu X, Zhou J, Abid MD, Yan H, Huang H, Wan L, Feng Z, Chen J. Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells. PLoS One. 2014; 9: e93974. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77450 | - |
dc.description.abstract | 實驗目的
阿茲海默症 (Alzheimer’s disease, AD) 是一種神經退化性疾病,是最常造成失智 (dementia) 的疾病因素,會表現漸進式記憶喪失及認知障礙。臨床上,阿茲海默症的病理特徵為β-amyloid (Aβ) 老年斑塊之沉積、神經細胞內表現過度磷酸化Tau蛋白所聚集成的神經纖維糾結 (NFTs) 及乙醯膽鹼 (acetylcholine) 含量減少。美國食品藥物管理局 (Food and Drug Administration, FDA) 認可已上市的藥物有五種分別為donepezil、rivastigmine、galantamine、memantine、namzaric,然而這些藥物僅能減緩症狀無法完全根治阿茲海默症;因此科學家們仍致力於找尋有效治療阿茲海默症的藥物。石斛成分moscatilin被指出具有抗發炎、解熱等許多藥理活性,然而還沒有關於抗阿茲海默症之研究發表。 實驗方法 本研究利用兩種阿茲海默症模式細胞株,其一為細胞轉染pRK5-EGFP-Tau P301L 和pCAX-FLAG-APP兩質體,將神經細胞株過度表現Aβ前身蛋白APP與易磷酸化之突變tau蛋白,建立阿茲海默症模式神經細胞株;另一種為外加okadaic acid (OA) ,抑制蛋白磷酸酶,進而磷酸化tau蛋白,兩種模式皆會引起tau蛋白磷酸化以及誘發一系列激酶如GSK3β的異常活化,以此建立阿茲海默症模式。以西方墨點法觀察moscatilin在神經細胞株中減少Tau蛋白磷酸化與其蛋白異常聚集之情形;並觀察moscatilin對於抑制蛋白激酶磷酸化tau蛋白之作用,更進一步以流式細胞儀觀察細胞凋亡情形。在活體實驗中,利用腹腔注射scopolamine誘發阿茲海默症,建立認知障礙之小鼠模型,藉由莫式水迷宮與舉臂式十字迷宮確認moscatilin改善認知能力,並以西方墨點法及免疫組織染色法確認神經保護之效果。 實驗結果 結果顯示moscatilin能顯著減少tau磷酸化表現量,更進一步減少tau在細胞中堆積的程度,並呈現time-和dose-dependent的情形。而後又觀察到moscatilin具有抑制GSK3β和MAPK/ERK路徑異常活化的激酶之效果,以這樣的抑制效果改善tau過度磷酸化的情形,接著實驗結果顯示moscatilin有減少細胞凋亡之能力。動物試驗結果透過莫式水迷宮及舉臂式十字迷宮呈現,moscatilin具有改善小鼠認知記憶學習之能力,而後西方墨點法與免疫組織染色法之結果皆顯示小鼠腦中moscatilin減少tau蛋白的磷酸化,且異常活化的激酶也與細胞實驗有相同的被抑制效果。 結論 利用細胞轉染pRK5-EGFP-Tau P301L及pCAX-FLAG- APP兩質體與外加OA兩種阿茲海默症模式,moscatilin會透過抑制GSK3β活性及減少JNK、ERK、p38磷酸化,顯著地減少tau蛋白磷酸化,並減少細胞內tau蛋白聚集,更進一步減少神經細胞凋亡情形。而後動物實驗證明moscatilin能改善小鼠空間學習記憶,並改善小鼠腦中病理變化,證明moscatilin具有神經保護效果,因此證實moscatilin是具有潛力能改善阿茲海默症之天然活性物質。 | zh_TW |
dc.description.abstract | Objective:Alzheimer’s disease (AD) is a neurodegenerative disease which is the most common cause of dementia that manifests as progressive memory loss and cognitive decline. Pathologically, AD is characterized by β-amyloid (Aβ) accumulation, tau aggregations and dysfunction of Ach and NMDA receptor. Currently, there is still an urgent need to find potential strategies to treat for AD. This study is to examine the neuroprotective effects of moscatilin, a bibenzyl extraction from orchid Dendrobium loddigesii or Dendrobium nobile. Moscatilin was reported used to reduce fever and has exerted anti-inflammatory actions, yet none research studies about the relationship with AD.
Methods:In this study, we used two methods to mimic AD-like models in vitro. One is co-transfection of pRK5-EGFP-Tau P301L and pCAX-FLAG-APP plasmids making the neuron cells overexpress amyloid precursor protein (APP) and mutant tau protein. The other is adding okadaic acid (OA) to induce phosphorylation of tau protein. Both of the methods result in the hyperphosphorylation of tau protein and trigger the activity of GSK3β, the main kinase indicated to cause phosphorylation of tau protein. We used western blot analysis to detect the protein expression and flow cytometry assay to investigate the apoptotic cells. Furthermore, we used a scopolamine-induced model as cognitive impairment in mice to investigate the neuroprotective effects of moscatilin. Result:We found that moscatilin significantly reduces the expression of phospho-tau in a time- and dose-dependent manner and further decreased the tau aggregation. Results showed that moscatilin reverses the tauopathy through the inactivation of GSK3β and MAPK/ERK pathway. Furthermore, we observed that moscatilin decreased the percentage of apoptotic cells induced by OA. The in vivo results indicated that moscatilin ameliorates learning and memory impairments in mice via Morris water maze and elevated plus maze. The IHC staining of mice hippocampus and western blot results of mice brain also confirmed the neuroprotective effects of moscatilin. Conclusion:Moscatilin significantly decreased tau phosphorylation after co-transfection of pRK5-EGFP-Tau P301L and pCAX-FLAG-APP and OA treatment. The inhibition of tau phosphorylation is through GSK3β inactivation and downregulation of JNK, ERK, p38 phosphorylation. Moscatilin decreased cellular tau aggregation and also reduced neuron cell apoptosis in vitro. Furthermore, moscatilin significantly ameliorated the spatial memory impairment in vivo. Moscatilin therefore demonstrates therapeutic potential for AD. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T22:02:33Z (GMT). No. of bitstreams: 1 ntu-107-R05423013-1.pdf: 3240429 bytes, checksum: 687281747ab6eb538b1bc12a2f75f642 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 縮寫表 I
中文摘要 III 英文摘要 V 第一章 研究動機與目的 1 第二章 文獻回顧 2 第三章 實驗材料與方法 23 第四章 實驗結果 33 第五章 討論 39 第六章 結論與未來展望 45 參考文獻 66 | |
dc.language.iso | zh-TW | |
dc.title | 探討石斛成分Moscatilin在阿茲海默症的神經保護作用之研究 | zh_TW |
dc.title | The study of neuroprotective effects of moscatilin in Alzheimer’s disease | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭哲志(George Hsiao),潘秀玲(Shiow-Lin Pan) | |
dc.subject.keyword | 阿茲海默症,石斛,tau蛋白,岡田酸,東莨菪鹼, | zh_TW |
dc.subject.keyword | Alzheimer’s disease,moscatilin,tau,okadaic acid,scopolamine, | en |
dc.relation.page | 78 | |
dc.identifier.doi | 10.6342/NTU201804260 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2018-11-05 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-R05423013-1.pdf 目前未授權公開取用 | 3.16 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。